OSTARINE MK-2866 STUDIES

Ostarine has completed Phase II studies for COPD, cachexia cancer (mixed-loss mixed-dose if desired), NSCLC (a type of lung cancer) that was successful and believe there are Phase III studies in time (they hold the cards close to the body for that sort of thing).

SARMs as doping

Not unexpectedly, these substances are now used as doping substances, and Ostarine mk-2866 is only the first example. Although it is formally possible to test it (Thevis et al, 2011), WADA’s laboratories, as far as I know, have not yet implemented a firm test for this. And there are several substances in this group of drugs. Smaller 20 of these drugs are now in clinical trials.

Effectively, Ostarine MK-2866 should bind testosterone, although it did not convert to estrogen and dihydrotestosterone, saving some of the side effects associated with these conversions.

SARMs are, in addition to their clinical application, today’s anabolic steroids. There are new molecules that can bind the androgen receptor without being steroids.